Los Angeles Capital Management
TBPH icon

Los Angeles Capital Management’s Theravance Biopharma TBPH Stock Holding History

Los Angeles Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Buy
199,589
+25,054
+14% +$443K 0.01% 406
2025
Q4 		$2.5M Sell
174,535
-6,942
-4% -$115K 0.01% 407
2025
Q3 		$2.65M Buy
181,477
+161,627
+814% +$2.04M 0.01% 434
2025
Q2 		$219K Buy
+19,850
New +$193K ﹤0.01% 1163
2024
Q3 		– Sell
-33,760
Closed -$286K – 1296
2024
Q2 		$286K Buy
+33,760
New +$305K ﹤0.01% 1029

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's TBPH Position: Q1 2026 in Review

Los Angeles Capital Management increased its Theravance Biopharma (TBPH) stake by 14% in Q1 2026, buying an estimated $443K and bringing the position to 199,589 shares worth $3.24M. The position accounts for 0.01% of the portfolio, ranked #406.

Los Angeles Capital Management first reported a position in TBPH in Q2 2024 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Los Angeles Capital Management held 199,589 shares of Theravance Biopharma worth $3.24M as of Q1 2026.
  • Los Angeles Capital Management bought 25,054 Theravance Biopharma shares in Q1 2026, an estimated $443K.
  • Theravance Biopharma made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #406 holding.
  • Los Angeles Capital Management first reported a position in Theravance Biopharma in Q2 2024 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.